FOXO4-DRI comes up often in discussions of cellular senescence research, and readers searching for it typically want to know whether it has been through clinical testing. It has not: there is no approved label and no registered clinical trial record for this compound.
Key takeaways
- FOXO4-DRI has no FDA-approved label, brand name, or approved indication.
- No clinical trials for FOXO4-DRI are currently registered.
- It is a large peptide, with a molecular formula of C228H388N86O64 and a molecular weight of about 5,358.
- Its structure can be referenced by PubChem CID 167312269.
- FOXO4-DRI remains an unapproved research compound, not a reviewed medical product.
What FOXO4-DRI is
FOXO4-DRI is a synthetic peptide, built from a long chain of amino acid residues as reflected in its molecular formula and structure. No FDA-reviewed label exists for this compound, so there is no official mechanism of action, drug class, or indication on file. Any description of its biological activity outside of a reviewed label falls outside the scope of verified label data.
Trial footprint
Public registries show zero registered clinical trials for FOXO4-DRI as of the data retrieval date. No trial samples, phases, or statuses are available to summarize. This absence of trial activity is itself a key data point for anyone evaluating the compound's research status.